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Reduced sexual function may have negative implications on health related quality of life 41 
among lymphoma survivors. A national cross-sectional study among long-term 42 
lymphoma survivors after high-dose therapy with autologous stem-cell transplantation 43 
auto-SCT treated during 1987-2008 was conducted in 2012-2014. The current study 44 
explored sexual functioning among these survivors. Sixty-six percent (n=159) of eligible 45 
men with complete questionnaire data were included, median age was 55 years. The 46 
Brief Sexual Function Inventory (BSFI) was used to assess sexual function and sexual 47 
satisfaction, compared with age-matched controls. In addition, sexual problems were 48 
defined based on predetermined cut-off values for BSFI domain scores. Sexual drive and 49 
erections firm enough to have sexual intercourse were reported to be present only a few 50 
days or less last month among 30% and 41% of survivors, respectively. Sexual 51 
satisfaction was reported by 39% of survivors. The survivors had significantly lower 52 
scores on all BSFI domains and an increased risk of problems with sexual drive and 53 
erection compared with controls. In multivariable models, cardiovascular disease was 54 
significantly associated with worse erectile function, while age >55 years, chronic 55 
fatigue, and physical inactivity were significantly associated with lower sexual 56 
functioning overall. Chronic fatigue and anxiety were related to lower sexual 57 
satisfaction.  58 
  59 
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Introduction  60 
Lymphoma therapy, in particular high-dose therapy with autologous stem-cell 61 
transplantation (auto-SCT), is associated with multiple long-term adverse effects, 62 
including sexual problems [1], which is important for quality of life (QoL) in lymphoma 63 
survivors [2, 3]. After conventional chemotherapy, 22-50% of non-Hodgkin lymphoma 64 
(NHL) and Hodgkin lymphoma (HL) survivors report reduced sexual function [4, 5, 2]. 65 
Among 246 male lymphoma survivors , reduced sexual function was associated with 66 
increasing age, low testosterone levels, poor physical health and increased mental 67 
distress (mean 14.8 years post-treatment) [6]. Reduced sexual function in HL survivors 68 
(n=3208) with up to 27 months follow-up, was associated with advanced stage disease, 69 
older age, pre-treatment sexual function and reduced health related QoL [2].  70 
In male stem-cell transplanted (SCT) cancer survivors, reduced sexual function is 71 
frequent, with lack of sexual drive, erectile dysfunction (ED) and sexual dissatisfaction 72 
being the most common problems median 3 years post-SCT [7, 8]. However, sexual 73 
problems related to graft-versus-host disease dominate the reports [9-12].  74 
Thus, there is a need for studies on sexual function in large samples of auto-SCT 75 
male lymphoma survivors, with long follow-up time [1, 12-15]. In addition, lymphoma 76 
patients have increased risk of cardiovascular disease (CVD), of which ED is an 77 
independent predictor in the general population [16]. However, the association between 78 
sexual function and CVD has not previously been studied in male lymphoma survivors. 79 
Our primary aim was to evaluate sexual functioning and sexual satisfaction 80 
among male long-term lymphoma survivors after auto-SCT, and to compare the findings 81 
to those of normative controls. Our secondary aim was to investigate the associations 82 
between survivors’ characteristics, especially psychological and somatic status including 83 




Subjects and methods 86 
Study sample 87 
During 2012-2014, a cross-sectional study was conducted at all four centers responsible 88 
for auto-SCT of lymphoma patients in Norway. Eligible subjects were lymphoma 89 
survivors (≥18 years) treated with auto-SCT during 1987-2008, alive per 31.12.2012 90 
[17, 18]. Pre-established exclusion criteria were active cancer treatment and unknown 91 
address. Overall, 242 eligible male survivors received postal invitation, of whom 77% 92 
(n=187) completed a questionnaire (Figure 1). Those also treated with allogeneic-SCT 93 
(n=16), total brain irradiation (n=1) or who delivered an incomplete Brief Sexual 94 
Function Inventory (BSFI) (n=9) were excluded. In addition, two males with active 95 
cancer treatment were identified during data preparation for the current study. The 96 
remaining 159 male participants represented the sample included in the analyses. 97 
Overall 148 (93%) of these men also participated in a clinical examination with height, 98 
weight and blood pressure measurement in addition to blood sampling. Information on 99 
lymphoma diagnosis and treatment was collected retrospectively from medical records 100 
[19]. 101 
Controls 102 
Normative data on sexual function using the BSFI from a sample of Norwegian males 103 
aged 20-59 years were available (n=3494). The questionnaire was mailed and the 104 
respondents returned it anonymously. Total respondent rate was 34%, and among men 105 
without cancer a valid BSFI questionnaire was obtained from 27% (n=929) [20]. 106 
Response rate varied according to age and was lowest among 20-29 years old (19%) 107 
increasing to 50-59 years (37%) and decreased among those >70 years (29%). 108 
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Frequency matching was performed with 10-year intervals, with three times as many 109 
controls as survivors randomly drawn within each interval. 110 
Measurements 111 
Fasting blood samples were collected before 10.00 AM. Testosterone, sex hormone-112 
binding globulin (SHBG) and luteinizing hormone (LH) were measured at one 113 
laboratory, using Roche E-platform. Free androgen index (FAI) was calculated: 114 
testosterone*10/ SHBG. We categorized gonadal hormonal status according to age-115 
specific reference values [21] of FAI and LH: 1) normal FAI + normal LH, 2) normal FAI + 116 
elevated LH, 3) low FAI + any level of LH and 4) ongoing testosterone replacement 117 
therapy. 118 
 The participants completed a multi-instrument questionnaire (125-items), 119 
including information on educational level, relationship status, current medication, the 120 
BSFI [20], Type-D14 for type D personality [22], Fatigue Questionnaire (FQ) [23], 121 
Hospital Anxiety and Depression Score (HADS) [24] and items on physical activity [25] 122 
and smoking. Details on study questionnaire, instruments (Type-D14, FQ), physical 123 
activity) and operationalization related to the instruments in addition to data on 124 
prevalence of chronic fatigue and associated factors in auto-SCT lymphoma survivors of 125 
both gender have been presented previously [18, 26].  126 
The BSFI is an 11-item questionnaire on sexual experiences the last 30 days. The 127 
instrument constitutes three functional domains (drive 2 items, erection 3 items, 128 
ejaculation 2 items), one problem assessment domain (one item on drive, erection and 129 
ejaculation, respectively), and one item on overall sexual satisfaction [27]. Participants 130 
rated their responses from 0-4, with 0 presenting the poorest function, biggest problem 131 
or least satisfaction, and 4 the opposites. We calculated domain scores by adding values 132 
for corresponding items divided by number of items (range 0-4), and a total BSFI score 133 
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(adding all values except sexual satisfaction, range 0-40) as a measure of overall sexual 134 
functioning. Due to some difference in answer alternatives on item 7 (Figure 1) between 135 
survivors and controls, score 2 and 3 were merged for controls. Caseness was not part of 136 
the original BSFI, but has been described as a method to compare sexual problems 137 
between cases and controls [28]. Total sum score for each domain was calculated, and 138 
cut-off values for caseness (problem) were defined as; drive ≤3, erection ≤7, ejaculation 139 
≤5, satisfaction ≤1. In addition, a combined sum score for drive, erection and ejaculation 140 
(DEE) was created and problem defined as DEE ≤10. A problem with overall sexuality 141 
was defined as the presence of either a satisfactory problem and/or a DEE problem.  142 
The HADS assess anxiety (seven items) and depression (seven items), item 143 
agreement scored 0-3 with a possible range 0-21. Cut-off for anxiety or depression 144 
caseness was ≥8 for both conditions.  145 
Cronbach’s coefficient alpha was calculated to assess internal consistency: BSFI 0.94, 146 
Type-D personality; negative affectivity 0.90 and social inhibition 0.88, FQ total score 147 
0.93 and HADS anxiety 0.83, depression 0.81. 148 
 149 
Cardiovascular comorbidity  150 
Information about CVD and risk factors were based on physicians’ report (transient 151 
ischemic attack, stroke, angina pectoris and myocardial infarction), examinations 152 
(height and weight for calculation of BMI), blood samples or medication (hypertension, 153 
diabetes type 1 or 2 and hypercholesterolemia) when available (n=149), and self-154 
reported data for the remaining participants (n=12). Obesity was defined as body mass 155 
index ≥30, kg/m2. Hypertension, hypercholesterolemia or diabetes were defined as 156 
systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg (three 157 
consecutive measurements, mean value of last two), low-density lipoprotein ≥4.1 158 
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mmol/L (160 mg/dL) and hemoglobin A1c ≥6.5% or fasting glucose ≥7.0 mmol/L, 159 
respectively as previously described [17].  160 
In order to elaborate on cardiovascular risk and sexual function, we constructed a 161 
categorical variable with 4 groups: 1) neither cardiovascular risk factors (smoking, 162 
obesity, hypertension or hypercholesterolemia), diabetes type 1 or 2, nor CVD (angina 163 
pectoris, myocardial infarction, transient ischemic attack or stroke); 2) ≥1 164 
cardiovascular risk factor, but no diabetes or CVD; 3) prevalent diabetes type 1 or 2; 4) 165 
prevalent CVD.  166 
 167 
Medication interfering with sexual function 168 
The following medications were considered to have possible adverse effects on sexual 169 
functioning: antidepressants, benzodiazepines, antipsychotics, morphine, beta-blockers, 170 
thiazide diuretics, and spironolactone [29, 30], while pro-erectile medication was 171 
sildenafil and tadalafil. A categorical variable with four groups was constructed; 1) no 172 
medication interfering with sexual function (none); 2) medication with possible adverse 173 
effects on sexual function; 3) testosterone replacement therapy; and 4) pro-erectile 174 
medication. Men who used testosterone replacement therapy were categorized as such, 175 
regardless of other medication interfering on sexual function. 176 
 177 
Statistics 178 
Descriptive characteristics were presented as numbers (percent) for binary variables, 179 
median (range) for age and time variables and mean (standard deviation) for the BSFI 180 
scores. Independent sample t-test with equal variances not assumed was used to 181 
compare means between normally distributed data. We performed age-stratified binary 182 
logistic regression, age-adjusted and multivariable analyses using linear regression 183 
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models to assess associations between independent and outcome variables, presented 184 
with odds ratio (OR) [95% confidence intervals] or unstandardized regression 185 
coefficient beta. We added a quadratic term of age and time to assess non-linearity. The 186 
multivariable models were adjusted for age, relationship status and level of education. 187 
Variables with a p-value ≤0.25 in age-adjusted models were included as independent 188 
variables in a multivariable model. A backward selection process was performed.  189 
Effect sizes were used as a measure to evaluate clinical significance and were 190 
reported as standardized mean difference with standard deviations of the controls as 191 
denominator due to heteroscedacity, equation:  192 
 𝑆𝑆𝑆𝑆𝑆𝑆 = 𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠− 𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑐𝑐𝑠𝑠𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑐𝑐𝑠𝑠 
𝑆𝑆𝑆𝑆𝑐𝑐𝑠𝑠𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑐𝑐𝑠𝑠
 [31, 32]. Effect size was considered to have none (0-193 
0.20), moderate (0.21-0.49) and considerable (ES ≥0.50) clinical significance [33].  194 
A two-sided p-value ≤0.05 was considered statistically significant. SPSS version 195 
25 was used as statistical software (IBM Corporation, Armonk, New York, USA).  196 
 197 
Ethics 198 
Approval from Regional Ethics Committee South East (no #2011/1353) and a written 199 
informed consent prior to inclusion from all study participants were obtained. 200 
 201 
Results 202 
Attrition analysis 203 
Respondents were significantly older compared with non-respondents at diagnosis, at 204 
auto-SCT and at survey, (median age was 42 vs 38 years, 45 vs 41 years and 55 vs 49 205 
years, respectively). No significant differences in lymphoma entities, number of 206 
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treatment regimes prior to auto-SCT, myeloablative regimen, or radiotherapy were 207 
found. 208 
 209 
Study sample characteristics 210 
Median age at survey for included survivors was 55 years and median time from auto-211 
SCT to survey was 8.1 years (Table 1). Two participants were <18 years at diagnosis (10 212 
and 13 years) and transplanted 29 and 19 years old, respectively. Low FAI was present 213 
in 15% of the survivors and 5% received testosterone replacement treatment. Anxiety, 214 
depression and chronic fatigue caseness were present in 14%, 14% and 27%, 215 
respectively, 52% had ≥1 cardiovascular risk factor and 13% had CVD. Fifty-five percent 216 
of survivors were sedentary with a level of physical activity below recommendations 217 
[19]. In total, 18% of survivors were smoking daily or occasionally. 218 
Among survivors, 75% were in a relationship (married or cohabitant) and 47% 219 
had completed more than 12 years of education (primary and secondary school), the 220 
corresponding numbers were 86% and 72% for controls.  221 
 222 
Sexual outcomes  223 
Thirty percent of survivors reported sexual drive only a few days or less last month, and 224 
41% reported erections firm enough to have sexual intercourse only a few times or less 225 
last month. Sexual satisfaction was reported by 39% of the survivors (Figure 2). 226 
Survivors had lower score on all BSFI items and sexual domains compared with controls 227 
(all p-values <0.001) (Figure 3, Table 2) and the differences in domain scores were 228 
clinically significant. Effect size for overall sexual functioning declined with increasing 229 
age, while the opposite was the case for sexual satisfaction. The two participants <18 230 
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years at diagnosis reported higher BSFI scores than mean of the 20-40 year old 231 
survivors (data not shown).  232 
Among the survivors, 43% had sexual drive problems, 54% had erectile 233 
problems, and 40% overall sexual problems (Table 3). The corresponding proportions 234 
among controls were 24%, 31% and 19%. The probability of a sexual problem among 235 
survivors was 3-5 fold increased for all domains in comparison to controls (Figure 4, 236 
Table 3). Age-stratified comparisons to controls showed greatest increased risk for 237 
sexual drive problems among men 41-65 years old, and greatest increased risk of 238 
erectile and satisfactory problems among men >65 years (Table 3).  239 
 240 
Medication interfering on sexual function 241 
In total, 127 men (80%) reported no current medication or no medication likely to 242 
interfere on sexual function, 21 men (13%) used medication with a possible adverse 243 
effect on sexual function and three men (2%) used pro-erectile medication. Eight men 244 
(5%) used testosterone replacement therapy. 245 
  246 
Factors associated with sexual outcomes  247 
In age-adjusted analyses, longer time since auto-SCT, TBI or subdiaphragmal irradiation, 248 
chronic fatigue, anxiety symptoms, diabetes type I or II, CVD, medication with possible 249 
adverse effect on sexual function, testosterone replacement therapy, low FAI and being 250 
sedentary were significantly associated with a lower sexual functioning overall, in 251 
addition to age >55 years.  Longer time since auto-SCT, subdiaphragmal irradiation, 252 
type-D personality, chronic fatigue, anxiety, CVD and low FAI were significantly 253 
associated with lower sexual satisfaction (Table 4).  254 
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 In multivariable models age >55 years, chronic fatigue and presence of CVD was 255 
negatively associated with lower erectile function, while age >55 years, chronic fatigue, 256 
medication with possible adverse effect on sexual function, testosterone replacement 257 
therapy, and a sedentary lifestyle were significantly associated with a lower sexual 258 
functioning overall. Chronic fatigue was significantly associated with a lower overall 259 
sexual satisfaction (Table 4). 260 
 261 
Discussion 262 
In this considerable sample of male auto-SCT lymphoma survivors, 40% had overall 263 
sexual problems, and both functioning and satisfaction were reduced compared with 264 
age-matched controls. 265 
There is a lack of studies comparing sexual function among auto-SCT lymphoma 266 
survivors with controls. However, supporting our findings are studies reporting on a 267 
sexual functioning inferior to controls in both lymphoma survivors who did not have 268 
auto-SCT and survivors of hematological malignancies after SCT [6, 10]. Compared with 269 
lymphoma survivors not treated with auto-SCT, sexual functioning might be even worse 270 
in our study group, as indicated by a comparison of effect sizes [6].  271 
Stratified by age, we observed an increasing difference in erectile function and 272 
sexual satisfaction between survivors and controls with increasing age groups, despite 273 
the opposite trend for assessment of sexual problems. Expectations of normal sexual 274 
functioning are likely to differ between age groups, leading to a response shift where the 275 
older survivors report less problems related to a certain reduction in sexual function, 276 
than younger survivors. In addition, the younger survivors might have been more 277 
resilient to functional reductions before satisfaction was affected.  278 
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The associations found in age-adjusted models reflect the multifactorial (social, 279 
psychological and physiological) interactions on sexual function also described in the 280 
general population [34, 29]. 281 
In multivariable models, survivors aged 41-55 years did not differ in sexual 282 
outcomes compared with the reference group (survivors age 26-40 years), however a 283 
significant worsening was found for patients above the age of 55 years. A relationship 284 
between increasing age and reduced sexual functioning is well known in the general 285 
population [34] and from previous reports on lymphoma survivors [6, 2]. Reduced 286 
physical health, adverse effects of multipharmacy in the elderly, decrease in testosterone 287 
and lack of partner may contribute to this finding [35].  288 
In this study, chronic fatigue was significantly associated with lower sexual 289 
functioning and satisfaction, in line with earlier findings [36], and this illustrates the 290 
detrimental effect chronic fatigue has on many aspects of life.  291 
Thirteen percent of survivors had CVD with a significant negative association 292 
with erectile function. Atherosclerosis as well as endothelial dysfunction are common 293 
causes of both CVD and ED [37]. Hence, these conditions share many risk factors. ED 294 
precedes CVD by 2-5 years [16], and we believe this is of special importance as auto-SCT 295 
lymphoma survivors are at increased risk of fatal CVD [1, 38].  296 
 The majority of survivors were sedentary with reduced overall sexual functioning 297 
compared with the physically active survivors. Contrasting earlier reports, physical 298 
inactivity was not related to ED in particular [39]. Sedentary survivors had a reduced 299 
sexual function that they considered more problematic compared with the physically 300 
active. However, the sedentary survivors did not report lower sexual satisfaction than 301 
the physically active survivors. 302 
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In age-adjusted analyses, low FAI was related to lower sexual functioning overall 303 
and less sexual satisfaction. These significant associations were lost in multivariable 304 
models indicating that factors described above were more important than FAI for sexual 305 
outcomes. Our findings are diverging from previous reports describing associations 306 
between sexual function and testosterone levels [6, 40]. We present two plausible 307 
explanations: 1) Low FAI seems to be associated with CVD [41], a factor included in our 308 
multivariable analyses, and 2) a small proportion of survivors had gonadal dysfunction 309 
in our study, reducing the power to detect a significant association.  310 
 All auto-SCT lymphoma survivors treated in Norway until 2008 were accounted 311 
for and invited to participate in the survey. A high participation rate assures good 312 
representativeness, and external validity of our results. With long follow-up time, 313 
reversible aspects of sexual functions should be restored after treatment. In addition, 314 
long follow-up time enables us to examine the association between CVD and ED. 315 
The BSFI is a validated instrument with good psychometric properties, and using 316 
a control group reporting on the same instrument is a considerable strength, especially 317 
in an area where a diversity of instruments have been used. The response rate in the 318 
control group was low, which is a problem with questionnaire studies of sexuality in the 319 
general population. Additionally, the representativeness was unknown [20]. However, 320 
the normative data resemble findings in a similar American study using the BSFI with 321 
better response rate [42]. Hence, we believe the control group was adequate, but we 322 
advise for careful interpretations. In addition, differences in education and relationship 323 
status between survivors and controls might represent selection bias.   324 
Further limitations include the cross-sectional design that prevents us from 325 
addressing causality. Adding medication in the multivariable models in order to adjust 326 
for possible effects on sexual function might have diminished the associations between 327 
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both CVD and mental distress with the sexual outcomes as co-linearity between these 328 
variables are likely to be present. Our outcomes of interest were based on patient 329 
reported outcome measures, which are associated with recall difficulties [43]. The 330 
sample size of young survivors was small hence, statistical analyses on effect size are 331 
uncertain.  332 
Clinical implications 333 
Erectile dysfunction might be a symptom of silent CVD and addressing sexual function at 334 
consultations may reveal auto-SCT survivors in need of support for lifestyle changes or 335 
medical intervention in order to ameliorate cardiovascular risk factors and possibly 336 
avoid or delay CVD events [30, 44, 45]. In particular, physical activity might have 337 
positive implications for CVD, chronic fatigue and anxiety that are more prevalent in SCT 338 
survivors [15], and perhaps erectile function can be improved [39]. Treatment for sexual 339 
problems should be offered according to previously published guidelines [46]. First, 340 
assessment of gonadal function and testosterone replacement therapy should be 341 
considered. Second, in case of erectile dysfunction use of pro-erectile medication 342 
(assuming no contraindications) or use of a vacuum erectile device is recommended and 343 
finally survivors with relational or psychosocial problem should be referred to 344 
individual or couple counseling.  345 
Conclusion 346 
Our study identifies sexual dysfunction as a problem for many male auto-SCT survivors, 347 
however sexuality is a neglected issue during follow-up [47]. Hence, physicians should 348 
address sexual function before, during, and after treatment in order to identify sexual 349 
problems and their cause in auto-SCT survivors. By acknowledging the importance of 350 
sexual function after cancer, we believe that more auto-SCT male survivors will have 351 
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Figure Legends  478 
Figure 1 Flowchart. Auto-SCT, high-dose chemotherapy with autologous stem-cell 479 
transplantation; SCT, stem-cell transplantation; agg NHL, aggressive non-Hodgkin 480 
lymphoma; HL, Hodgkin lymphoma; TBI, total body irradiation; BSFI, Brief Sexual 481 
Function Inventory. *Two non-eligible survivors were identified during data assessment 482 
for the present study, hence they were excluded from analyses. 483 
 484 
Figure 2 Male lymphoma survivors treated with high-dose chemotherapy with 485 
autologous stem-cell transplantation response to the Brief Sexual Function Inventory 486 
items. 487 
 488 
Figure 3 Brief Sexual Function Inventory (BSFI) mean item score in male lymphoma 489 
survivors treated with high-dose chemotherapy with autologous stem-cell 490 
transplantation (n=159) and controls (n=477). 491 
 492 
Figure 4 Odds Ratio and 95% Confidence Interval [95%] for Brief Sexual Function 493 
Inventory (BSFI) problem* among male lymphoma survivors treated with high-dose 494 
chemotherapy with autologous stem-cell transplantation, reference = controls. 495 
*Categorized as problem (caseness) if total score on current domain: Sexual drive ≤3; 496 
erectile function ≤7; ejaculatory function ≤5; DEE (drive, erection, ejaculation) problems 497 
≤10; sexual satisfaction ≤1; overall sexual problem= either DEE problem or overall 498 




Table 1 Characteristics of study sample at diagnosis and survey, and normative controls 






SOCIODEMOGRAPHICS   
Age at diagnosis, years, median (range) 42.0 (10-65)  
Age at auto-SCT,  years, median (range) 45.0 (18-67)  
Age at survey, years, median (range)  55.0 (26-77) 55.0 (20-79) 
Time auto-SCT – survey, years, median (range)   8.2 (3.2-23)  
In a relationshipi 119 (75) 412 (86) 
Education >12 years 74 (47) 343 (72) 
LYMPHOMA AND TREATMENT   
Lymphoma entity   
     Aggressive Non-Hodgkin lymphomaii 108 (68)  
     Indolent Non-Hodgkin lymphomaiii 15 (9.4)  
     Hodgkin lymphoma 36 (23)  
Stage at diagnosis:   
     I-II 51 (32)  
     III-IV 108 (68)  
Treatment regimes prior to auto-SCT   
     1 56 (35)  
     2 79 (50)  
     ≥3 24 (15)  
Radiotherapy   
     None 61 (38)  
     Otheriv 1 (0.6)  
     Supradiaphragmalv 37 (23)  
     Total body irradiationvi 25 (16)  
     Subdiaphragmalvii 35 (22)  
Myeloablative regime   
     BEAM 132 (83)  
     Total body irradiation 27 (17)  
Curable diseaseviii 102 (64)  
Relapse after auto-SCT 27 (17)  
HORMONAL STATUS AND THERAPY*   
Gonadal statusix   
     Normal FAI and LH 79 (50)  
     Normal FAI and elevated LH 32 (20)  
     Low FAI and any level of LH 24 (15)  
Testosterone replacement therapy 8 (5.0)  
COMORBIDITY   
Type-D personalityx 33 (21)  
Chronic fatigue 43 (27)  
Anxiety caseness 22 (14)  
Depression caseness 22 (14)  
Cardiovascular risk or diseasexi   
     None 44 (28)  
     ≥1 Cardiovascular risk factorxii 82 (52)  
     Diabetes type 1 or 2 13 (8.2)  
     Cardiovascular diseasexiii 20 (13)  
MEDICATION INTERFERING WITH SEXUAL FUNCTION   
     None 127 (80)  
2 
 
     Possible adverse effect on sexual functionxiv 21 (13)  
     Testosteron replacement therapyxv 8 (5.0)  
     Pro-erectile medicationxvi 3 (1.9)  
LIFESTYLE BEHAVIOR   
Sedentaryxvii 87 (55)  
Smokingxviii 29 (18)  
Abbreviations: Auto-SCT, high-dose chemotherapy with autologous stem-cell 
transplantation; BEAM, high-dose chemotherapy regime (carmustine, etoposide, cytarabine 
and melphalan); FAI, free androgen index; LH, luteinizing hormone.  
Missing values among cases: In a relationship, n=1; income, n=3; gonadal hormonal status, 
n= 16; Type D personality, n=12; chronic fatigue, n=1; hypercholesterolemia, n=11; 
myocardial infarction, n=1; sedentary, n=3; 
Missing values among controls: In a relationship, n=3; education, n=6.  
*N=143 because 16 participants did not have blood samples available. 
Data are presented as numbers (%) unless otherwise specified. 
i Survivors: Married or cohabitant. Controls: Married or in an intimate relationship. 
ii Includes: Lymphoblastic lymphoma, n=13; Burkitt lymphoma, n=8; diffuse large B-cell lymphoma, n=27; 
mantle cell lymphoma, n=30; T-cell lymphomas, n=16; transformed lymphoma, n=12, other (not specified), 
n=2. 
iii Includes follicular or other indolent lymphomas. 
iv Irradiated field unknown. 
v Irradiated fields supradiaphragmal: ear/nose/throat/thyroideal, n=3; collum, n=9; supra/infraclavicular, n=12; 
axillar, n=9; columna, n=3, mediastinal, n=20; mantle field, n=4; other, n=8; 
vi Two of the TBI treated participants also received subdiaphragmal irradiation and was categorized in that 
group, hence they do not appear in this group. Additional irradiated fields: collum, n=1; supra/infraclavicular, 
n=1, other, n=1. 
vii Irradiated fields subdiaphragmal: Abdominal, n=20; paraaortal, n=1; reversed Y, n=2, pelvic, n=4, groin, n=5; 
spleen, n=1, lower extremities, n=2. Additional irradiated fields supradiaphragmal: ear/nose/throat, n=1; 
collum, n=5; supra/infraclavicular, n=6; columna, n=3; mediastinal, n=5, mantle field, n=4; other, n= 6.  Total 
body irradiation, n=2. 
viii Curable: lymphoblastic lymphoma, Burkitt lymphoma, diffuse large B-cell lymphoma, T-cell lymphoma; 
palliative: follicular or other indolent lymphoma, mantle cell lymphoma, transformed lymphoma. 
ix Survivors on testosterone replacement therapy excluded. According to age-specific reference values: FAI: 20-
29, 4.8-13.6; 30-39 years, 3.8-11.0; 40-49 years, 3.1-9.1; 50-59 years, 2.7-7.7; 60-69 years, 2.3-6.5; 70-79 years, 
2.1-5.5. LH IU/L: 20-29, 1.95-9.4; 30-39 years, 1.93-9.7; 40-49 years, 1.95-10.0; 50-59 years, 2.01-10.4; 60-69 
years, 2.10-10.8; 70-79 years, 2.22-11.2. 
x Type-D personality; negative affectivity and social inhibition. 
xi Survivors with risk factors or diabetes type 1 or 2 in addition to disease were categorized as disease. 
xii Risk factors: Obesity (body mass index >30) (n=18), smoking daily or occasionally (n=26, of note three 
smokers were categorized as cardiovascular disease hence do not appear here), hypertension (n=36), 
hypercholesterolemia (n=43, 5 missing). 
xiii Disease: Stroke or transitory ischemic attack (n=10), angina pectoris (n=8) or myocardial infarction (n=7, 1 
missing). Four males had >1 disease, hence appear in more than one group. 
xiv Antidepressant (n=3), benzodiazepines (n=5), antipsychotics (n=1) morphine (n=1) beta-blocker (n=11), 
thiazide diuretics (n=6), spironolactone (n=1). Four males used more than one of these medications, hence 
appear in more than one group.  
xv  Four of these men used additional medication interfering with sexual function: case 1, thiazide diuretics and 
beta-blocker; case 2, beta-blocker, antidepressant and morphine; case 3, antidepressiva; case 4, tadalafil.  
xvi Sildenafil (n=2), tadalafil (n=2), one male used both medications. 
xvii Physical activity less than 150 min/week of moderate activity, or less than 75 min of strenuous activity 
xviii Daily or occassionally. 
                                                            
Table 2 BSFI outcomes (sexual function domains, total BSFI score and sexual satisfaction) among male auto-SCT lymphoma survivors and 
normative controls, overall and age-stratified 
 Sexual drive 
 








TOTAL SAMPLE       
Auto-SCT survivors (n=159) 1.81 (0.95) 2.22 (1.36) 2.72 (1.41) 2.56 (1.27) 23.4 (10.8) 1.97 (1.22) 
Controls (n=477) 2.24 (0.83) 2.94 (1.11) 3.46 (0.82) 3.21 (1.04) 29.9 (8.53) 2.61 (1.05) 
p-value* <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
SMD# -0.52 -0.65 -0.90 -0.63 -0.76 -0.61 
YOUNG (20-40 years)       
Auto-SCT survivors (n=18) 2.47 (1.04) 3.17 (1.08) 3.53 (0.79) 2.93 (1.23) 30.3 (9.14) 2.11 (1.28) 
Controls (n=55) 2.65 (0.80) 3.60 (0.57) 3.85 (0.34) 3.65 (0.68) 34.8 (4.60) 2.60 (1.05) 
p-value* 0.50 0.12 0.11 0.03 0.06 0.15 
SMD# -0.23 -0.75 -0.94 -1.06 -0.98 -0.47 
MIDDLE-AGED (>40-55 years)       
Auto-SCT survivors (n=65) 2.12 (0.77) 2.78 (1.13) 3.28 (0.95) 2.77 (1.25) 27.5 (9.39) 2.23 (1.14) 
Controls (n=191) 2.52 (0.71) 3.40 (0.80) 3.77 (0.45) 3.57 (0.70) 33.5 (5.81) 2.78 (0.98) 
p-value* <0.001 <0.001 <0.001 <0.001 <0.001 0.001 
SMD # -0.56 -0.78 -1.09 -1.14 -1.03 -0.56 
OLD (>55-65 years)       
Auto-SCT survivors (n=49) 1.50 (0.95) 1.80 (1.34) 2.16 (1.61) 2.35 (1.33) 19.8 (10.9) 1.86 (1.29) 
Controls (n=128) 2.07 (0.74) 2.67 (1.04) 3.35 (0.86) 3.03 (1.13) 28.0 (8.43) 2.55 (1.10) 
p-value* <0.001 <0.001 <0.001 0.002 <0.001 0.001 
SMD # -0.77 -0.84 -1.38 -0.60 -0.97 -0.63 
OLDEST (>65 years)       
Auto-SCT survivors (n=27) 1.19 (0.75) 0.99 (0.84) 1.85 (1.46) 2.16 (1.10) 15.5 (7.67) 1.44 (1.12) 
Controls (n=103) 1.70 (0.82) 2.05 (1.22) 2.84 (1.04) 2.54 (1.22) 22.8 (9.21) 2.39 (1.10) 
p-value* 0.003 <0.001 0.002 0.13 <0.001 <0.001 
SMD # -0.62 -0.87 -0.95 -0.31 -0.79 -0.86 
Abbreviations: BSFI, Brief Sexual Function Inventory; Auto-SCT, high-dose chemotherapy with autologous stem-cell transplantation; SMD, 
standardized mean difference.  
Range score possible: sexual drive 0-4, erectile function 0-4, ejaculatory function 0-4, problem assessment 0-4, total BSFI score 0-40, sexual 
satisfaction 0-4. 
Bold type indicating statistical significance (p-value <0.05) or considerable clinical significance (effect size ≥0.50). 
Data are presented as mean (SD) unless otherwise specified. 
*Independent sample t-test, equal variances not assumed.  




Table 3 Age-stratified odds ratios for BSFI caseness (problem) comparing auto-SCT lymphoma survivors with normative controls using logistic 
regression models 
 DOMAIN PROBLEM 








TOTAL SAMPLE,  
n=159 cases/477 controls 
      
     Auto-SCT survivors 69 (43) 86 (54) 59 (37) 41 (26) 55 (35) 63 (40) 
     Controls 114 (24) 148 (31) 80 (17) 42 (8.8) 74 (16) 90 (19) 












YOUNG SAMPLE (20-40 years) 
n=18 cases/55 controls 
      
     Auto-SCT survivors 3 (17) 5 (28) 4 (22) 1 (5.6) 5 (28) 5 (28) 
     Controls 8 (15) 4 (7.3) 1 (1.8) 0 8 (15) 8 (15) 
     Odds Ratio [95%CI], reference = controls NA NA NA NA NA NA 
MIDDLE-AGED SAMPLE (>40-55 years) 
n=65 survivors/191 controls 
      
     Auto-SCT survivors 18 (28) 23 (35) 13 (20) 6 (9.2) 16 (25) 17 (26) 
     Controls 19 (9.9) 23 (12) 9 (4.7) 1 (0.5) 23 (12) 23 (12) 










OLD SAMPLE (>55-65 years) 
n=49 survivors/128 controls 
      
     Auto-SCT survivors 28 (57) 34 (69) 24 (49) 19 (39) 20 (41) 24 (49) 
     Controls 36 (28) 55 (43) 27 (21) 12 (9.4) 23 (18) 25 (20) 












OLDEST SAMPLE (>65 years) 
n=27 survivors/103 controls 
      
     Auto-SCT survivors 20 (74) 24 (89) 18 (67) 15 (56) 14 (52) 17 (63) 
     Controls 51 (50) 66 (64) 43 (42) 29 (28) 20 (19) 34 (33) 












Abbreviations: BSFI, Brief Sexual Function Inventory; auto-SCT, high-dose chemotherapy with autologous stem-cell transplantation; DEE, drive, 
erection and ejaculation; NA, not applicable. 
*Age-adjusted. 
Bold type indicating statistical significance (p-value <0.05). 
Data are presented as numbers (%) unless otherwise specified. 
 
Table 4. Association between BSFI outcomes (function domains, total BSFI score and sexual satisfaction) and characteristics of study sample 
(n=159), A) age-adjusted and B) multivariable linear regression models 
 Mean Sum  
Sexual Drive 
 















      
SOCIODEMOGRAPHICS       
Age at auto-SCT, per 10 years -0.25 [-0.36, -0.14] -0.43 [-0.58, -0.28] -0.40 [-0.56, -0.25] -0.14 [0.29, 0.00] -3.02 [-4.23, -1.80] -0.14 [-0.28, 0.00] 
Age at survey       
   26 – 40 years 0 Ref. 0 Ref. 0 Ref. 0 Ref. 0 Ref. 0 Ref. 
  >40 – 55 years -0.36 [-0.81, 0.09] -0.38 [-0.99, 0.22] -0.24 [-0.91, 0.42] -0.16 [-0.81, 0.50] -2.82 [-7.84, 2.21] 0.12 [-0.51, 0.75] 
  >55 – 65 years -0.97 [-1.44, -0.51] -1.36 [-1.99, -0.74] -1.37 [-2.05, -0.68] -0.57 [-1.25, 0.11] -10.5 [-15.7, -5.26] -0.25 [-0.91, 0.40] 
  >65 years -1.29 [-1.80, -0.77] -2.18 [-2.87, -1.49] -1.68 [-2.44, -0.92] -0.77 [-1.51, -0.02] -14.8 [-20.5, -9.02] -0.67 [-1.39, 0.05] 
Time auto-SCT – survey, per 5 
years 
-0.16 [-0.28, -0.04] -0.21 [-0.37, -0.05] -0.16 [-0.34, 0.02] -0.18 [-0.35, 0.00] -1.78 [-3.11, -0.45] -0.18 [-0.35, -0.02] 
In a relationshipi -0.23 [-0.54, 0.09] 0.00 [-0.43, 0.42] -0.11 [-0.57, 0.36] -0.06 [-0.52, 0.41] -0.84 [-4.38, 2.70] -0.14 [-0.58, 0.30] 
Education > 12 years -0.31 [-0.58, -0.04] -0.16 [-0.53, 0.21] -0.09 [-0.50, 0.31] -0.19 [-0.59, 0.21] -1.86 [-4.92, 1.20] -0.24 [-0.62, 0.15] 
LYMPHOMA AND TREATMENT       
Lymphoma entity       
   Aggressive NHLii 0 Ref. 0 Ref. 0 Ref. 0 Ref. 0 Ref. 0 Ref. 
   Indolent NHLiii 0.35 [-0.12, 0.82] 0.20 [-0.43, 0.83] 0.31 [-0.38, 1.01] 0.08 [-0.60, 0.77] 2.19 [-3.06, 7.44] 0.11 [-0.55, 0.77] 
   Hodgkin lymphoma -0.08 [-0.43, 0.27] -0.34 [-0.81, 0.13] -0.11 [-0.62, 0.41] -0.17 [-0.68, 0.34] -1.90 [-5.79, 1.99] -0.02 [-0.51, 0.47] 
Stage III-IV at diagnosis 0.11 [-0.19, 0.40] -0.08 [-0.48, 0.33] 0.09 [-0.35, 0.53] 0.10 [-0.34, 0.53] 0.46 [-2.88, 3.79] -0.09 [-0.50, 0.33] 
Treatment regimes prior to 
auto-SCT 
      
   1 0 Ref. 0 Ref. 0 Ref. 0 Ref. 0 Ref. 0 Ref. 
   2 0.00 [-0.30, 0.30] -0.10 [-0.50, 0.31] -0.20 [-0.65, 0.24] -0.19 [-0.62, 0.24] -1.24 [-4.60, 2.11] 0.06 [-0.36, 0.48] 
   ≥3 0.05 [-0.37, 0.47] -0.15 [-0.71, 0.42] -0.05 [-0.66, 0.57] 0.36 [-0.25, 0.96] 0.64 [-4.04, 5.31] 0.25 [-0.34, 0.84] 
TBI myeloablative regimeniv -0.26 [-0.62, 0.11] -0.17 [-0.66, 0.32] -0.28 [-0.81, 0.26] -0.34 [-0.87, 0.19] -2.59 [-6.65, 1.46] -0.15 [-0.66, 0.36] 
Radiotherapy       
   None 0 Ref. 0 Ref. 0 Ref. 0 Ref. 0 Ref. 0 Ref. 
   Other NA NA NA NA NA NA 
   Supradiaphragmal -0.20 [-0.59, 0.18] -0.40 [-0.91, 0.12] -0.54 [-1.10, 0.02] -0.38 [-0.95, 0.18] -3.83 [-8.10, 0.43] -0.27 [-0.81, 0.27] 
   Total body irradiation -0.49 [-0.90, -0.08] -0.52 [-1.07, 0.03] -0.79 [-1.39, -0.20] -0.57 [-1.17, 0.03] -5.84 [-10.4, -1.32] -0.49 [-1.06, 0.09] 
   Subdiaphragmal -0.30 [-0.66, 0.06] -0.46 [-0.94, 0.02] -0.58 [-1.10, -0.06] -0.36 [-0.88, 0.17] -4.21 [-8.16, -0.25] -0.54 [-1.04,- 0.04] 
COMORBIDITY       
Type-D personalityv -0.25 [-0.60, 0.11] -0.44 [-0.91, 0.03] -0.28 [-0.80, 0.24] -0.51 [-1.01, 0.00] -3.89 [-7.78, 0.00] -0.56 [-1.04, -0.07] 
Chronic fatigue caseness -0.19 [-0.50, 0.11] -0.53 [-0.94, -0.13] -0.44 [-0.88, 0.01] -0.46 [-0.90, -0.02] -4.23 [-7.58, -0.88] -0.64 [-1.05, -0.22] 
Anxiety caseness -0.16 [-0.56, 0.23] -0.62 [-1.15, -0.10] -0.64 [-1.22, -0.07] -0.60 [-1.17, 0.03] -5.26 [-9.62, -0.91] -0.78 [-1.32, -0.23] 
Cardiovascular risk or diseasevi       
   None 0 Ref. 0 Ref. 0 Ref. 0 Ref. 0 Ref. 0 Ref. 
  Cardiovascular risk 0.07 [-0.25, 0.38] -0.07 [-0.49, 0.34] -0.01 [-0.47, 0.44] -0.16 [-0.61, 0.30] -0.59 [-4.03, 2.85] -0.02 [-0.46, 0.42] 
   Diabetes type 1 or 2 -0.41 [-0.96, 0.13] -0.79 [-1.49, -0.08] -0.70 [-1.48, 0.09] -0.47 [-1.25, 0.32] -5.99 [-11.9, -0.09] -0.44 [-1.20, 0.31] 
   Cardiovascular disease -0.27 [ -0.73, 0.19] -1.02 [-1.62, -0.43] -0.91 [-1.58, -0.25] -0.86 [-1.55, -0.22] -7.84 [-12.8, -2.91] -0.81 [-1.44, -0.17] 
MEDICATION       
None 0 Ref. 0 Ref. 0 Ref. 0 Ref. 0 Ref. 0 Ref. 
Noxious on sexual functioning -0.53 [-0.92, -0.13] -0.80 [-1.33, -0.27] -0.70 [-1.29, -0.12] -0.55 [-1.12, 0.03] -6.49 [-10.9, -2.12] -0.37 [-0.93, 0.19] 
Testosteron substitution -0.37 [-0.99, 0.25] -0.80 [-1.63, 0.02] -0.92 [-1.83, -0.01] -1.28 [-2.17, -0.39] -8.84 [-15.6, -2.04] -0.88 [-1.76, -0.01] 
Pro-erectile medication NA NA NA NA NA NA 
GONADAL HORMONAL 
STATUSvii 
      
Hormonal groupsviii       
   Normal FAI and LH 0 Ref. 0 Ref. 0 Ref. 0 Ref. 0 Ref. 0 Ref. 
   Normal FAI, elevated LH 0.19 [-0.20, 0.57] 0.08 [-0.47, 0.62] -0.15 [-0.71, 0.42] -0.16 [-0.67, 0.35] -0.17 [-4.51, 4.17] -0.02 [-0.51, 0.46] 
   Low FAI, any level of LH -0.27 [-0.70, 0.15] -0.69 [-1.30, -0.08]  -0.60 [-1.23, 0.04] -0.40 [-0.97, 0.17] -5.02 [-9.87, -0.17] -0.74 [-1.29, -0.20] 
LIFESTYLE BEHAVIOR       
Sedentaryix -0.29 [-0.56, -0.02] -0.39 [-0.76, -0.03] -0.63 [-1.03, -0.24] -0.53 [-0.92, -0.14] -4.60 [-7.59, -1.62] -0.19 [-0.57, 0.19] 
B) MULTIVARIABLE 
MODELSx 
      
SOCIODEMOGRAPHICS       
Age at survey       
    26 – 40 years 0 Ref. 0 Ref. 0 Ref. 0 Ref. 0 Ref. 0 Ref. 
  >40 – 55 years -0.23 [-0.69, 0.22] -0.09 [-0.68, 0.50] -0.04 [-0.73, 0.64] 0.08 [-0.60, 0.75] -0.14 [-5.18, 4.89] 0.31 [-0.32, 0.95] 
  >55 – 65 years -0.88 [-1.35, -0.41] -1.13 [-1.74, -0.51] -1.27 [-1.98, -0.56] -0.38 [-1.08, 0.32] -8.91 [-14.1, -3.73] -0.20 [-0.85, 0.46] 
  >65 years -1.07 [-1.57, -0.56] -1.92 [-2.57, -1.26] -1.46 [-2.22, -0.70] -0.57 [-1.32, 0.18] -12.6 [-18.2, -7.01] -0.58 [-1.29, 0.13] 
In a relationship   -0.22 [-0.53, 0.08] -0.03 [-0.44, 0.38] -0.13 [-0.59, 0.33] -0.07 [-0.46, 0.45] -0.94 [-4.36, 2.47] -0.12 [-0.55, 0.32] 
Education > 12 years -0.28 [-0.55, -0.01] 
Ble sign 
-0.07 [-0.42, 0.29] -0.10 [-0.51, 0.30] -0.11 [-0.51, 0.29] -1.16 [-4.13, 1.82] -0.17 [- 0.55, 0.21] 
COMORBIDITY       
Chronic fatigue  -0.53 [-0.91, -0.14]   -3.75 [-7.01, -0.47] -0.66 [-1.08, -0.24] 
Cardiovascular risk or diseaseviii         
   None  0 Ref.     
   Cardiovascular risk  -0.02 [-0.43, 0.38]     
   Diabetes type 1 or 2  -0.57 [-1.26, 0.13]     
   Cardiovascular disease  -0.87 [-1.48, -0.26]       
MEDICATION INTERFERING 
WITH SEXUAL FUNCTION 
      
    None 0 Ref. 0 Ref. 0 Ref. 0 Ref. 0 Ref. 0 Ref. 
    Possible adverse effect on       
sexual function 
-0.47 [-0.86, -0.09] -0.69 [-1.21, -0.17] -0.62 [-1.21, -0.04] -0.48 [-1.06, 0.10] -6.42 [-10.7, -2.14] -0.44 [-0.99, 0.11] 
    Testosteron substitution -0.23 [-0.83, 0.38] -0.51 [-1.32, 0.30] -0.82 [-1.72, 0.09] -1.20 [-2.09, -0.30] -7.90 [-14.5, -1.25] -0.79 [-1.66, 0.07] 
    Pro-erectile medication NA NA NA NA NA NA 
LIFESTYLE BEHAVIOR       
Sedentaryx -0.29 [-0.56, -0.03]  -0.62 [-1.02, -0.22] -0.49 [-0.88, -0.09] -4.02 [-6.97, -1.07]  
Abbreviations: BSFI, Brief Sexual Function Inventory; auto-SCT, high-dose chemotherapy with autologous stem-cell transplantation; TBI, total 
body irradiation; NA, not applicable; FAI, free androgen index; LH, luteinizing hormone. 
Range score possible: sexual drive 0-4, erectile function 0-4, ejaculatory function 0-4, problem assessment 0-4, total BSFI score 0-40, sexual 
satisfaction 0-4. 
Bold type indicating statistical significance (p-value <0.05). 
Italic type indicating p-value <0.25. 
Data are presented as unstandardized coefficient beta [95% Confidence Interval], unless otherwise specified. 
i Married or cohabitant. 
ii Includes: Lymphoblastic lymphoma, n=13; Burkitt lymphoma, n=8; diffuse large B-cell lymphoma, n=27; mantle cell lymphoma, n=30; T-cell lymphomas, n=16; transformed 
lymphoma, n=12, other (not specified), n=2. 
iii Follicular or other indolent lymphomas. 
iv TBI vs. BEAM (high-dose chemotherapy regime (carmustine, etoposide, cytarabine and melphalan)). 
v Type-D personality; negative affectivity and social inhibition. 
vi None, neither risk nor disease; Cardiovascular risk, either obesity (body mass index >30), smoking, hypertension, or hypercholesterolemia; diabetes type 1 or 2; 
cardiovascular disease, either transitory ischemic attack, stroke, angina pectoris or myocardial infarction. 
                                                        
                                                                                                                                                                                                                                                                          
vii Age was omitted as covariate in order to avoid over-adjustment as hormonal status was operationalized based on age-specific reference values. 
viii Survivors on testosterone replacement therapy excluded. According to age-specific reference values: FAI: 20-29, 4.8-13.6; 30-39 years, 3.8-11.0; 40-49 years, 3.1-9.1; 50-
59 years, 2.7-7.7; 60-69 years, 2.3-6.5; 70-79 years, 2.1-5.5. LH IU/L: 20-29, 1.95-9.4; 30-39 years, 1.93-9.7; 40-49 years, 1.95-10.0; 50-59 years, 2.01-10.4; 60-69 years, 2.10-
10.8; 70-79 years, 2.22-11.2. 
ix Physical activity less than 150 min/week of moderate activity, or less than 75 min of strenuous activity. 
x Adjusted for age, relationship, education and medication interfering with sexual function performed backward selection were variables with p-value<0.25 were included. 
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1. On how many days have you felt sexual drive?
2. How would you rate your level of sexual drive?
3. How often have you had partial or full erections when you
were sexually stimulated in any way?
4. When you had erections how often were they firm enough to
have sexual intercourse?
5. How much difficulty did you have getting an erection'?
6. How much difficulty have you had ejaculating when you have
been sexually stimulated?
7. How much did you consider the amount of semen you
ejaculated to be a problem for you?
8. To what extent have you considered a lack of sex drive to be a
problem?
9. To what extent have you considered your ability to get and
keep erections to be a problem?
10. To what extent have you considered your ejaculation to be a
problem?
11. Overall, how satisfied have you been with your sex life?
1:no days; 2: none at all; 3-4: not at all; 5: did not get erections at all; 6: no sexual stimulation; 7-10: big problem; 11: very dissatisfied.
1: few days; 2: low; 3-4: a few times; 5-6: a lot of difficulty; 7-10: medium problem; 11: mostly dissatisfied.
1: some days; 2: medium; 3-4: fairly often; 5-6: some difficulty; 7-10: small problem; 11: neutral or mixed.
1: most days; 2: medium high; 3-4: usually; 5-6: little difficulty; 7-10: very small problem; 11: mostly satisfied.
1: every day; 2: high; 3-4: always; 5-6: no difficulty; 7-10: no problem; 11: very satisfied.
 
Figure 3 
 Abbreviations: BSFI, Brief Sexual Function Inventory; Auto-SCT, high-dose chemotherapy with autologous 
stem-cell transplantation. 
The difference between survivors and controls was statistically significant (p<0.001) on all items. 
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1: During the past 30 days, on how many days have you felt
sexual drive?
2: During the past 30 days, how would you rate your level of
sexual drive?
3: Over the past 30 days, how often have you had partial or full
sexual erections when you were sexually stimulated in any way?
4: Over the past 30 days, when you had erections, how often
were they firm enough to have sexual intercourse?
5: How much difficulty did you have getting an erection during
the past 30 days?
6: In the past 30 days, how much difficulty have you had
ejaculating when you have been sexually stimulated?
7: In the past 30 days, how much did you consider the amount of
semen you ejaculate to be a problem for you?
8: In the past 30 days, to what extent have you considered a lack
of sexual drive to be a problem?
9: In the past 30 days,to what extent have you considered  your
ability to get and keep erection to be a problem?
10: In the past 30 days, to what extent have you considered your
ejaculation to be a problem?
11: Overall, during the past 30 days, how satisfied have you been
with you sex life?

















0 - 4 (never or poore function - always or good function)
RESPONS SCORE; 
0 - 4 (big problem - no problem)
RESPONS SCORE; 
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----------- Increased risk survivors -----------><----- Decreased risk survivors ---
